JAMDA
Volume 7, Issue 5 , Pages 315-318 , June 2006

Quality Improvement Case Study: Warfarin Sodium Interactions

  • Andrew D. Weinberg, MD, FACP, CMD

      Affiliations

    • University of South Carolina School of Medicine, Columbia, SC
    • Dorn VA Medical Center, Columbia, SC
    • Corresponding Author InformationAddress correspondence to Andrew W. Weinberg, MD, FACP, CMD, Geriatrics 171, Dorn VA Medical Center, 6439 Garners Ferry Road, Columbia, SC 29209.
    • ,
  • Julie S. Altman, PharmD

      Affiliations

    • South Carolina College of Pharmacy, Columbia, SC
    • ,
  • Jean K. Pals, RN, BC, BSN

      Affiliations

    • Dorn VA Medical Center, Columbia, SC
    • University of South Carolina, College of Nursing, Columbia, SC

References 

  1. Petersen P , Boysen G , Godtfredsen J , et al.   Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation . Lancet . 1989;1:175–179
  2. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation . N Engl J Med . 1990;323:1505–1511
  3. Stroke Prevention in Atrial Fibrillation Investigators . Stroke Prevention in Atrial Fibrillation study (Final results) . Circulation . 1991;84:527–539
  4. Ezekowitz MD , Bridgers SL , James KE , et al.   Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation . N Engl J Med . 1992;327:1406–1412
  5. Connolly SJ , Laupacis A , Gent M , et al.   Canadian atrial fibrillation anticoagulation (CAFA) study . J Am Coll Cardiol . 1991;18:349–355
  6. Atrial Fibrillation Investigators . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (Analysis of pooled data from five randomized controlled trials) . Arch Intern Med . 1994;154:1449–1457
  7. European Atrial Fibrillation Trial Study Group . Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke . Lancet . 1993;342:1255–1262
  8. Hart RG , Benavente O , McBride R , et al.   Antithrombotic therapy to prevent stroke in patients with atrial fibrillation (A meta-analysis) . Ann Intern Med . 1999;131:492–501
  9. Singer DE , Albers GW , Dalen JE , et al.   Antithrombotic therapy in atrial fibrillation (The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy) . Chest . 2004;126:429S–456S
  10. Hylek EM , Singer DE . Risk factors for intracranial hemorrhage in outpatients taking warfarin . Ann Intern Med . 1994;120:897–902
  11. Cannegieter SC , Rosendaal FR , Wintzen AR , et al.   Optimal oral anticoagulant therapy in patients with mechanical heart valves . N Engl J Med . 1995;333:11–17
  12. Ansell J , Hirsh J , Poller L , et al.   The pharmacology and management of the vitamin K antagonists (The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy) . Chest . 2004;126:204S–233S
  13. Thomson Micromedex, Greenwood Village, CO. Available at: www.thomsonmicromedex.com. 2005.

PII: S1525-8610(06)00183-6

doi: 10.1016/j.jamda.2006.04.004

JAMDA
Volume 7, Issue 5 , Pages 315-318 , June 2006

Article Tools